Archive


Category: Buy of The Week

Buy of The Week

  • Idexx Laboratories (IDXX)

    November 2, 2026

    Portfolio: Zacks Earnings Certain Core

    IDEXX Laboratories is the dominant franchise in companion animal diagnostics, a position built on a razor-and-blade model that creates an exceptionally deep moat. Its large installed base of in-clinic analyzers locks veterinary practices into high-margin, recurring consumable and reference-lab revenue, reinforced by practice management software and newer diagnostics such as Cancer Dx. This recurring diagnostic revenue gives the business rare visibility and resilience, since pet healthcare demand is structurally non-discretionary. The company’s 5-year historical earnings growth of +14.6% has meaningfully outpaced its industry’s 6.2%, and currently assigns the stock a Zacks Rank #2 (Buy) with an Earnings ESP of +0.59%, noting the company beat consensus EPS in each of the trailing four quarters with an average surprise of roughly 5.7%.

    The financial record validates the moat. From FY2016 to FY2025, revenue grew from $1.78B to $4.30B (a ~10% CAGR) while diluted EPS compounded ~20.5%, from $2.44 to $13.08; operating margin expanded from 20% to 32% and operating cash flow rose from $339M to $1.18B. Recent momentum remains intact: Q2 2026 revenue of $1.22B grew 9.7% year over year, EPS of $4.27 topped estimates, and return on invested capital (ROIC) has been maintained consistently at an exceptional 35-45%. Management raised FY2026 guidance to revenue of $4.70–$4.75B (9.1–10.3% reported, 8.5–9.7% organic). Consistent execution, double-digit guided growth, recurring-revenue durability, and expanding margins support a long-term compounder thesis; the principal risk is valuation, but with shares tracking sideways since 2021 while earnings steadily compound, the risk here is limited and a breakout in the near future is likely, in our view.